2.77

1.42% -0.04

After Hours: 2.72 -0.05 -1.81%

Cellectar Biosciences Inc (CLRB)

Overview News Price History Financials Discussions Forecast Stock Split

Cellectar Biosciences Inc stock is traded at $2.77, with a volume of 30,986. It is down -1.42% in the last 24 hours and up +6.95% over the past month. Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Previous Close:

$2.81

Open:

$2.8

24h Volume:

30,986

Relative Volume:

0.03

Market Cap:

$22.14M

Revenue:

Net Income/Loss:

$-20.84M

P/E Ratio:

-0.3756

EPS:

-7.3739

Net Cash Flow:

$-18.59M

1W Performance:

+6.54%

1M Performance:

+6.95%

6M Performance:

-13.98%

1Y Performance:

-42.29%

1-Day Range:

$2.66

$2.855

1-Week Range:

$2.5501

$3.08

52-Week Range:

$2.20

$6.52

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Name

Cellectar Biosciences Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(608) 441-8120

Address

100 CAMPUS DRIVE, FLORHAM PARK, NJ

Employee

Twitter

@CellectarBio

Next Earnings Date

2026-08-13

Latest SEC Filings

CLRB's Discussions on Twitter

Compare CLRB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLRB Cellectar Biosciences Inc	2.77	22.22M	0	-20.84M	-18.59M	-7.3739
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-26	Upgrade	Maxim Group	Hold → Buy
Dec-05-24	Resumed	Ladenburg Thalmann	Buy
Jul-01-20	Initiated	Oppenheimer	Outperform
Jan-21-20	Resumed	ROTH Capital	Buy
Sep-13-19	Initiated	ROTH Capital	Buy
Dec-21-16	Initiated	Ladenburg Thalmann	Buy

View All

Cellectar Biosciences Inc Stock (CLRB) Latest News

Jun 27, 2026

CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits

Jun 27, 2026

Price to book forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBIT forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView

Jun 26, 2026

Price to earnings forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView

Jun 26, 2026

Cellectar Biosciences, Inc. Actuals & Estimates (NASDAQ:CLRB) - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView

Jun 26, 2026

Jun 25, 2026

CLRB Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 18, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Jun 18, 2026